Longitudinal biomarkers—rebiopsy and circulating tumor DNA/Minimal Residual Disease—should be used to detect resistance mechanisms and adapt therapy (including rational combinations targeting PI3K/AKT/MAPK). Here, AKT1 is linked to neoplasm.